The estimated Net Worth of John O Jr Marsh is at least $442 Tysiąc dollars as of 22 August 2005. John Marsh owns over 5,000 units of Novavax stock worth over $442,440 and over the last 21 years John sold NVAX stock worth over $0.
John has made over 2 trades of the Novavax stock since 2003, according to the Form 4 filled with the SEC. Most recently John bought 5,000 units of NVAX stock worth $4,900 on 22 August 2005.
The largest trade John's ever made was buying 10,000 units of Novavax stock on 1 December 2003 worth over $31,300. On average, John trades about 1,071 units every 45 days since 2003. As of 22 August 2005 John still owns at least 36,000 units of Novavax stock.
You can see the complete history of John Marsh stock trades at the bottom of the page.
John's mailing address filed with the SEC is 560 NORTH LOUDON ST, , WINCHESTER, VA, 22601.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi oraz Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: